bsa angpt2  (Santa Cruz Biotechnology)

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: ANGPT2 expression in multiple tumors. (A) ANGPT2 levels in 18 human tumors using TCGA tumor and normal data. (B-H) ANGPT2 levels in TCGA; (B) CHOL, (C) ESCA, (D) GBM, (E) HNSC, (F) KICH, (G) KIRC and (H) STAD tissues vs. the matching TCGA and GTEx normal tissues. *P<0.05, **P<0.01 and ***P<0.001; all P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; TCGA, The Cancer Genome Atlas; CHOL, cholangiocarcinoma; ESCA, esophageal cancer; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; STAD, stomach adenocarcinoma.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Gene expression profiling interactive analysis database: OS and DFS analysis of ANGPT2 in diverse human tumors. (A-G) OS plot: ANGPT2 in (A) CHOL, (B) ESCA, (C) GBM, (D) HNSC, (E) KICH, (F) KIRC and (G) STAD. (H-N) DFS plot: ANGPT2 in (H) CHOL, (I) ESCA, (J) GBM, (K) HNSC, (L) KICH, (M) KIRC and (N) STAD. OS, Overall survival; DFS, disease-free survival; ANGPT2, angiopoietin-2; CHOL, cholangiocarcinoma; ESCA, esophageal cancer; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; STAD, stomach adenocarcinoma.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Gene Expression

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Association of ANGPT2 expression with clinical analysis in ESCA. (A-D) ANGPT2 expression in the GSE20347 , GSE38129 , GSE45670 and GSE70409 datasets. (E) Paired ANGPT2 expression in adjacent and tumor tissues. (F) Correlation between ANGPT2 expression and grade. (G) Impact of ANGPT2 expression on OS in patients with ESCA. (H) Multivariate Cox regression: Connection with OS and clinicopathologic characteristics in patients with ESCA. (I) Nomogram for the 1-, 3-, and 5-yr OS prediction of patients with ESCA. (J) Representative images and (K) statistical analysis: ANGPT2 expression in ESCA tumors and normal tissues. Scale bars, 50 µm. (K) Number of ANGPT2 expression negative or positive cases in normal tissues and ESCC tissues based on the IHC staining score results. The results demonstrated that 16 cases were negative and only 5 cases were positive for ANGPT2 expression in normal tissues, while merely 2 cases were negative and 19 cases were positive for ANGPT2 expression in ESCC tissues. (L) ANGPT2 protein expression in paired tissues obtained from patients with ESCA. (M) ANGPT2 mRNA expression levels in ESCA and paired adjacent normal tissues. (N) Kaplan-Meier: Prognosis of OS according to the IHC scores of ANGPT2. Statistical analyses: Paired Student's t-test was used for comparisons between paired tumor and normal tissues (E, L and M); unpaired Student's t-test was used for comparison of IHC scores between tumor and normal tissues (K); one-way ANOVA was used for analyzing ANGPT2 expression across different tumor grades (F); log-rank test was used for survival analyses (G and N); Cox proportional hazards model was used for multivariate regression analysis (H). *P<0.05 and **P<0.01; all P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; OS, overall survival; ESCC, esophageal squamous cell carcinoma; IHC, immunohistochemical.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing, Immunohistochemistry, Comparison, Immunohistochemical staining

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Upstream regulator of ANGPT2 in ESCA. (A) Cytoscape software: miRNA-ANGPT2 regulatory network. (B) Expression correlation between predicted miRNAs and ANGPT2 in ESCA. (C) Unsupervised hierarchical clustering heatmap based on the differentially expressed miRNAs between 185 ESCA tissues and 13 healthy tissues. (D) miR-145-5p level in ESCA and control normal samples. (E) Collation analysis: miR-145-5p and AMPKAPK5-AS1, as well as (F) miR-145-5p and SNHG1. (G) AMPKAPK5-AS1 and (H) SNHG1 expression levels in adjacent and tumor tissues. (I) Overall survival analysis: AMPKAPK5-AS1 and (J) SNHG1 in patients with ESCA. Statistical analyses: Unpaired Student's t-test was used for comparing lncRNA/miRNA expression levels between tumor and normal tissues (D, G and H); Spearman's rank correlation coefficient was used for evaluating correlations between gene expression levels (B, E and F); log-rank test was used for survival analyses (I and J). All P-values were adjusted for multiple comparisons using the Benjamini-Hochberg method to control the false discovery rate. All P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; miRNAs or miRs, microRNAs.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Software, Expressing, Control, Gene Expression

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Connection of ANGPT2 expression with immunity in ESCA. (A) GSEA enrichment plots showing signaling pathways significantly enriched in the ANGPT2 high-expression group (1,000 permutations were performed; pathways include ‘ALLOGRAFT_REJECTION’ and ‘INTERFERON_GAMMA_RESPONSE’, consistent with immune-related functions). (B-H) Spearman's correlation analysis between ANGPT2 expression and infiltration levels of specific immune cell subsets in ESCA (adjusted for tumor purity via TIMER2.0 or indicated algorithms): (B) CD8 + T cells (TIMER, Rho=0.220, P=2.04×10 −3 ); (C) myeloid dendritic cells (TIMER, Rho=0.286, P=9.76×10 −5 ); (D) macrophages (EPIC, Rho=0.211, P=2.87×10 −3 ); (E) macrophage/monocytes (MCPCOUNTER, Rho=0.178, P=1.67×10 −2 ), (F) neutrophils (TIMER, Rho=0.132, P=4.34×10 −2 ), (G) NK cells (EPIC, Rho=0.148, P=4.81×10 −2 ), (H) T follicular helper cells (CIBERSORT, Rho=0.260, P=3.68×10 −4 ). (I) Single-sample GSEA showing the abundance of 23 infiltrating immune cell subgroups in ANGPT2 high- vs. low-expression groups. (J) ESTIMATE algorithm analysis of Stromal Score, Immune Score and ESTIMATE Score in ANGPT2 high- vs. low-expression groups (P<0.01 for Stromal Score; P<0.05 for Immune Score; P<0.01 for ESTIMATE Score, as indicated by symbols). *P<0.05, **P<0.01 and ***P<0.001; all P-values are adjusted for multiple comparisons where applicable. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; GSEA, Gene Set Enrichment Analysis; NK, natural killer.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing, Protein-Protein interactions

Journal: Oncology Reports

Article Title: Unveiling the role of ANGPT2 in esophageal cancer: A prognostic factor and potential oncogene

doi: 10.3892/or.2026.9098

Figure Lengend Snippet: Relation of ANGPT2 level with immune checkpoint and chemotherapeutic sensitivity in ESCA. (A) TIMER-conducted Spearman correlation: ANGPT2 with CTLA-4 expression in ESCA. (B) TCGA-determined expression correlation: ANGPT2 with CTLA4 in ESCA. (C) TIMER-conducted Spearman correlation: ANGPT2 with HAVCR2 expression in ESCA. (D) TCGA-determined expression correlation: ANGPT2 with HAVCR2 in ESCA. (E) TIMER-conducted Spearman correlation: ANGPT2 with PDCD1LG2 expression in ESCA. All TIMER-conducted Spearman correlations were adjusted by purity. (F) TCGA-determined expression correlation: ANGPT2 with PDCD1LG2 in ESCA. (G-L) Relationships between both ANGPT2 expression groups and chemotherapeutic sensitivity. ANGPT2, angiopoietin-2; ESCA, esophageal cancer; TCGA, The Cancer Genome Atlas.

Article Snippet: The membranes were then incubated overnight at 4°C with primary antibodies diluted in TBST containing 5% BSA: ANGPT2 (1:1,000; cat. no. sc-74403; Santa Cruz Biotechnology, Inc.) and GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing

Journal: iScience

Article Title: Targeting of Itch by clomipramine or gene therapy improves cognitive defects related to Alzheimer’s disease

doi: 10.1016/j.isci.2026.115181

Figure Lengend Snippet: Clomipramine inhibits Itch and prevents neuronal apoptosis and cell cycle re-entry in neurons from TgAD mice (A) Chemical structure of clomipramine. The chloride moiety is proposed to interact with catalytic cysteine in the HECT domain of Itch. (B) Rat cortical neurons were treated with Aβ 42 and/or clomipramine (75 nM) for 48 h followed by 12 h treatment with the proteasome inhibitor MG132. TAp73 was immunoprecipitated, and western blotting was performed on TAp73-IP with anti-ubiquitin and anti-Itch antibodies. Total protein lysates were also used for western blotting with indicated antibodies. Ubiquitinated TAp73 levels were quantified by densitometry of ubiquitin immunoblot, normalized with respect to the input TAp73, which was also normalized with respect to actin (mean ± SEM, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, one-way ANOVA, Tukey’s test, N = 3). (C) Rat cortical neurons were treated with Aβ 42 and/or 75 nM clomipramine for 48 h followed by western blotting for indicated proteins. The levels of TAp73, PCNA, and cl_caspase3 were quantified by densitometry, and fold change with respect to untreated (ctrl) neurons was determined (mean ± SEM, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, one-way ANOVA, Tukey’s test, N = 3). (D) Cortical neurons from WT or TgAD mice were treated with 75 nM clomipramine for 48 h followed by western blotting for indicated proteins. TAp73, PCNA, and cl_caspase3 levels were quantified by densitometry, and fold change with respect to untreated WT neurons is provided (mean ± SEM, ∗ p < 0.05, ∗∗ p < 0.01, one-way ANOVA, Tukey’s test, N = 2).

Article Snippet: PCNA (Santa cruz, cat. no. sc-56; 1:500 for WB, 1:50 for IHC), cleaved caspase 3 (CST, cat. no. 966l; 1:1000 for WB), Itch (CST, cat. no. 12117; 1:1000 for WB), TAp73 (Novus, cat. no. NBP2-24737, 1:1000 for WB, 1:50 for IP), myc-tag (9B11) (CST, cat. no. 2276; 1:2000 for WB, 1:100 for IHC), NeuN (Novus, cat. no. NBP2-67314; 1:100 for IHC), Ubiquitin (Santa cruz, cat. no. sc-8017; 1:1000 for WB) and β-Actin (Santa cruz, cat. no. sc-47778, 1:2000 for WB).

Techniques: Immunoprecipitation, Western Blot, Ubiquitin Proteomics